Yantai Dongcheng Pharmaceutical Group Co., GMP Enoxaparin Sodium manufacture China，Ltd. (formerly known as “Yantai Dongcheng Biochemical Co., Ltd.) was established in 1998 and listed on the Shenzhen Stock Exchange (stock code: 002675) in May 2012. After over 20 years of development, Yantai Dongcheng Pharmaceutical Group Co., Ltd. has become a large pharmaceutical group covering four fields: biochemical APIs, chemical medicines, proprietary Chinese medicines and nuclide drugs, which integrates the research and development, production and sales of medicines.
The Group controls more than 40 subsidiaries, including Yantai Dongcheng Beifang Pharmaceutical Co., Ltd., Yantai Dongcheng Dayang Pharmaceuticals Co., Ltd., Linyi Dongcheng Dongyuan Biological Engineering Co., Ltd., Zhongtai Biological Chemical Products Co., Ltd., Dong Cheng International (HongKong) Limited, Chengdu Yunke Pharmaceutical Co., Ltd., Shanghai GMS Pharmaceutical Co., Ltd., Shanghai Yi Tai Pharmaceutical Technology Company Ltd., JYAMS Ltd., etc. The Group has set up the R&D branches and offices in Beijing, Shanghai and Nanjing and over two thousand employees.
As a leading biochemical API producer in China, Yantai Dongcheng Pharmaceutical Group Co., Ltd. has obtained the numerous international authoritative certifications by the excellent quality of its core products sodium heparin and chondroitin sulfate. Over 90% of the products are sold to more than 40 countries and regions in Europe, America, Asia Pacific and other parts of the world. Also, it has established the long-term and stable cooperation with many international prestigious pharmaceutical enterprises.
Dongcheng Pharmaceutical continues to strengthen the preparation business, and the preparation products cover the cardiovascular, antitumor, urology, orthopedics and other therapeutic areas. In recent years, the company has entered the nuclide drug industry from a high starting point, which has high technical barriers and high growth potential. It also has successively acquired a number of domestic nuclide drug enterprises, deployed the entire industry chain from diagnostic nuclide drug to therapeutic nuclide drug and established the company’s leading position in the nuclide drug field of China.
Dongcheng Pharmaceutical continuously increases the investment in scientific research, commits to the independent innovation, and introduce high-quality talents such as Mount Tai Scholars and 973 Scientists. Through the establishment of an extensive cooperation network of university, research and industry, it can realize the introduction and transformation of new technologies, and the innovation-driven enterprise development.
The company has won the honors of “Key High-tech Enterprise of National Torch Program”, “Provincial Level Enterprise Technology Center”, “Provincial Engineering Technology Research Center”, “Provincial Level Engineering Laboratory”, “Provincial Collaborative Innovation Center for Ocean Engineering Technology”, “Shandong Postdoctoral Innovation Practice Base”, “Shandong Technological Innovation Model Enterprise” and “China’s Top 100 Pharmaceutical Companies”.
Guided by the corporate mission of “Base in Orient, Commitment to Health”, Dongcheng Pharmaceutical will deepen the resource integration, optimize the industrial structure, and continuously improve the innovation capabilities and core competitiveness. With the “Global Heparin Specialist, China’s Nuclide Drug Leader” as the goal, the company advances towards growing into a pharmaceutical enterprise that is leading in the specialized domain and continues to create superior value.